AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05401630 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study Procedures
Description: All participants will answer a series of questionnaires that address several factors such as patient medical history, family history, medication usage, health behaviors, psychological factors, etc. Questionnaires related to symptoms, psychological factors, depression, anxiety, and quality of life will be taken.~All participants will undergo 123I-MIBG SPECT imaging in the morning in a fasting state. Mental Stress Testing will be conducted in the Laboratory in the morning after fasting for at least 4 hours and withdrawal of all vasoactive medications, caffeine, and tobacco 24-48 hours before testing. Participants will also undergo 1-week of Home Monitoring using a single-use, noninvasive, water-resistant, 7-day ambulatory ECG monitoring, which offers the advantage of direct access to raw data that can be downloaded from the device after use.~A 3-day food recall diary, cognitive assessments via the NIH Toolbox, and a Sleep diary during home monitoring will be collected.
Study NCT05401630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Procedures
Description: All participants will answer a series of questionnaires that address several factors such as patient medical history, family history, medication usage, health behaviors, psychological factors, etc. Questionnaires related to symptoms, psychological factors, depression, anxiety, and quality of life will be taken.~All participants will undergo 123I-MIBG SPECT imaging in the morning in a fasting state. Mental Stress Testing will be conducted in the Laboratory in the morning after fasting for at least 4 hours and withdrawal of all vasoactive medications, caffeine, and tobacco 24-48 hours before testing. Participants will also undergo 1-week of Home Monitoring using a single-use, noninvasive, water-resistant, 7-day ambulatory ECG monitoring, which offers the advantage of direct access to raw data that can be downloaded from the device after use.~A 3-day food recall diary, cognitive assessments via the NIH Toolbox, and a Sleep diary during home monitoring will be collected.
Study NCT06166576 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablative radioembolization
Description: The interventional radiologist utilizes a pre-test with 99mTc-MAA SPECT-CT and cone-beam CT for procedural planning. For tumors confined to a single segment, the treatment area is planned to receive a radiation dose of over 400 Gy using the single-compartment MIRD technique. For tumors extending beyond a single segment, the multi-compartment MIRD technique is used to plan a radiation dose of 700 Gy (± 20%) to the tumor. The upper limit for the estimated lung dose is set at 25 Gy, and the upper limit for the perfused non-tumoral liver dose is 250 Gy. In cases where tumors extending beyond a single segment cannot receive the planned dose of 700 Gy (± 20%) due to limits on lung or normal liver dose, the plan is adjusted to deliver the maximum dose to the tumor within the permissible range for lung and normal liver doses. Radioembolization is typically performed in a single session, and any methods not mentioned here should follow the instructions for use of TheraSphere.
Study NCT04608916 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Using surgical diathermy to make skin incision
Description: Using surgical diathermy to make skin incision during shoulder arthroplasty
Study NCT04608916 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Using scalpel blade to make skin incision
Description: Using scaple blade to make skin incision during shoulder arthroplasty
Study NCT04683796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100% Autologous platelet rich plasma
Description: Patients' blood (36 ml per tube) will be collected in three 50-ml sterile centrifuge tubes containing 4 ml of 3.2% buffered citrate acid for anticoagulation. Tubes will be centrifuged at 350 g for 10 minutes at 20 C. The two upper layers of the centrifuged blood, the plasma and the superficial buffy coat, will be separated in a sterile manner under a laminar air flow hood. A 1.5 ml aliquot of both final blood products will be transferred into identical opaque eye drop bottles, labelled name, hospital number, dated and sealed.
Study NCT04683796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100% Autologous serum
Description: Patients' blood (36 ml per tube) will be collected in three 50-ml sterile centrifuge tubes. The tubes will be left standing in an upright position for 1-2 hours to enable blood clot formation at room temperature (18-25 C). The tubes will be centrifuged at 3000 g for 30 minutes at 20 C. The supernatant serum will be aseptically transferred into a sterile syringe to enable filtration through a 0.2 µm pore size membrane filter under a laminar air flow hood. A 1.5 ml aliquot of both final blood products will be transferred into identical opaque eye drop bottles, labelled name, hospital number, dated and sealed.
Study NCT05798143 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated Repetitive Transcranial Magnetic Stimulation
Description: rTMS is a non-invasive brain stimulation technique. It will be used a MagPro R30 with the Cool-B-70 figure-of-eight coil (MagVenture, Falun, Denmark).
Study NCT04827758 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Screening and diagnostic tests for sarcopenia
Description: All of the following tests and questionnaires will be performed :~* SARC-F questionnaire,~* measurement of muscle strengh by a grip test,~* measurement of muscle mass by impedancemetry (ASM/size2),~* 4-meter walking speed test,~* Timed-Up and Go (TUG) test,~* ADL (Activities of Daily Living) and IADL (Instrumental Activities of Daily Living) questionnaires.
Study NCT01280071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminophylline
Study NCT06084702 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rehydration with plain water
Description: Plain water without calories, sweetener, or electolytes
Study NCT06084702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehydration Drink
Description: Roaring Water. An electrolyte drink with low Carbohydrate content
Study NCT04984122 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: LEEP
Description: According to the size of the cervix, a loop electrode size was selected. The electrical power for the loop electrode was set to 50 W cut and 45 W coagulation in blended mode. LEEP was performed by carefully passing the loop around the transformation zone from 12 o'clock to 6 o'clock. An additional top-hat excision was performed in patients with a lesion deep in the cervical canal. After completion of the excision, hemostasis was exclusively obtained using the ball electrode in spray coagulation mode. No suturing or other methods were used for hemostasis.
Study NCT05822193 — intervention group
Intervention type: OTHER
Intervention: Multiple exposures
Description: Exposures variables (observational study): age, gender, education, comorbidities, vaccination status, severity of the acute episode of COVID-19, treatments used for acute COVID-19.
Study NCT05276206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID , NALUFIN , local anesthetic andTAP Block
Description: The pain level of the cases is evaluated by means of the digital pain (numeric rating) scale from 0 to 10 in which 0 means no pain and 10 means the worst pain as well as the duration of pain relief and the need for another dose of the same analgesic or other. The pain level is evaluated again if it is present.~In all groups non steroidal anti-inflammatory drugs will be given as a rescue analgesic and the total dose will be calculated and compared
Study NCT06462898 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fortified Protein Smoothie
Description: Omega-3 powder and protein supplementation.
Study NCT06462898 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Non-Fortified Protein Smoothie
Description: Protein without omega-3 powder supplementation.
Study NCT04421352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1001
Description: low-dose radiation+CS1001 1200mg Q3W. In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~Dose A: 3Gy/1f; Dose B: 9Gy/3f; Dose C: 15Gy/5f;~In the dose expansion part, more SCLC patients will be assigned.
Study NCT05038683 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Holbæk Obesity Treatment
Description: Obesity is a chronic, progressive, severe, recidivistic, and complex disease, which mandates that children and adolescents with overweight or obesity have access to a professional medical healthcare service as other pediatric chronic diseases, implying a lifelong course of treatment. The HOT method is further based on the physiological insight into the endocrine regulation of fat mass; especially on how the body adapts when it is challenged by weight loss. These insights include an understanding where the body shifts into an energy-preserving mode when the individual is initiating weight-reducing actions, such as a reduced caloric intake or an increased level of physical activity, which has numerous impacts on communication and pedagogy.~HOT is administered by healthcare nurses and dietitians at healthcare centers in Danish municipalities. Each treatment will be conducted as face-to-face sessions totalling a range of six to 12 hours for 12 months.
Study NCT05038683 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Obesity Treatment
Description: Obesity is viewed as a chronic disease that is ultimately thought to result from an imbalance between energy intake and energy expenditure. However, multiple factors, both environmental and genetic, are thought to influence the disease as well. As obesity reflects energy imbalances, the treatment plan should be designed to induce a slightly negative energy balance by focusing on diet, physical activity, and inactivity through behavior change. Taking one step at a time, will in the end lead to the same energy balance result (i.e. weight loss) and will be more sustainable for the participant whose motivation is absolutely pivotal in this process.~COT is administered by healthcare nurses and dietitians at healthcare centers in Danish municipalities. Each treatment will be conducted as face-to-face sessions totalling a range of six to 12 hours for 12 months.
Study NCT05618288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile Health Breastfeeding Counseling
Description: a phone-based breastfeeding counseling intervention, delivered by labor and delivery nurses, nutritionists, and maternal and child health nurses.
Study NCT05618288 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care breastfeeding counseling
Description: The ongoing antenatal, delivery and postnatal breastfeeding and lactation counseling that is provided by the Naivasha sub-County Referral Hospital.
Study NCT02953496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vonapanitase
Description: Vonapanitase will be administered to the target lesion of the SFA or PA via percutaneous needle injection under ultrasound guidance.
Study NCT06344559 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: The study intervention involves modulation of cortical excitation to inhibition (E/I) balance in the right frontal eye field (FEF) by means of 2 trains of spaced continuous or intermittent theta burst stimulation (cTBS, iTBS, respectively) using a transcranial magnetic stimulation device. The endpoint of this stimulation will be a decrease (cTBS) or increase (iTBS) in the local E/I ratio that should last at least 60 minutes post-stimulation (Chung et al., 2016).~In separate sessions, all participants will receive either active or stimulation to the FEF. The Investigators will contrast the effects of both iTBS and cTBS to sham stimulation and to each other.
Study NCT06344559 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: The study intervention involves modulation of cortical excitation to inhibition (E/I) balance in the right frontal eye field (FEF) by means of 2 trains of spaced continuous or intermittent theta burst stimulation (cTBS, iTBS, respectively) using a transcranial magnetic stimulation device. The endpoint of this stimulation will be a decrease (cTBS) or increase (iTBS) in the local E/I ratio that should last at least 60 minutes post-stimulation (Chung et al., 2016).~In separate sessions, all participants will receive either active or stimulation to the FEF. The Investigators will contrast the effects of both iTBS and cTBS to sham stimulation and to each other.
Study NCT04694976 — intervention group
Intervention type: BIOLOGICAL
Intervention: 25-OH Vitamin D measure
Description: As a complement to the off-study prescription, the investigator are taking two 1 mL tubes of extra blood to measure vitamin D, calcium, phosphorus, parathyroid hormone (PTH) and creatinine.
Study NCT05139420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phentermine-topiramate combined with lifestyle intervention
Description: participants will be enrolled in a medical weight loss program and will be offered a 6 month prescription for phentermine-topiramate (note: The goal of the study is NOT to assess efficacy or safety of this drug) in addition to lifestyle advice.
Study NCT05139420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lifestyle intervention with meal replacement program
Description: participants will be enrolled in a medical weight loss program and will be given a 6 month subscription to a calorie-reduced meal replacement program, in addition to lifestyle advice.
Study NCT06449222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327 Dose Level 1 (DL1)
Description: Intravenous (IV) infusion
Study NCT06449222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327 Dose Level 1 (DL2)
Description: IV infusion
Study NCT06449222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-placlitaxel
Description: IV infusion
Study NCT06449222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion
Study NCT06449222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion
Study NCT06449222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion
Study NCT06449222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: IV infusion
Study NCT06449222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327 Optimized Dose
Description: IV infusion
Study NCT06449222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327 Equivalent Q3W Dose
Description: IV infusion
Study NCT05463731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remternetug (IV)
Description: Administered IV
Study NCT05463731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remternetug (SC)
Description: Administered SC
Study NCT05463731 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV or SC
Study NCT06470763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANV600
Description: ANV600 administered by intravenous (IV) infusion
Study NCT06470763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANV600 + pembrolizumab (KEYTRUDA®)
Description: ANV600 administered by intravenous (IV) infusion pembrolizumab (KEYTRUDA®) administered by intravenous (IV) infusion
Study NCT06541548 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HR-pQCT
Description: Xtreme CT® device is a high resolution peripheral quantitative computed tomography (HR-pQCT) used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.~For the study, the device will be used to assess bone density and microarchitecture at the forearm and shin for a systemic effect. In rheumatoid arthritis, bone density and microarchitecture will also be measured at the metacarpophalangeal.
Study NCT06541548 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pQCT
Description: Peripheral Quantitative Computed Tomography (pQCT) will be performed and measure bone and muscle parameters.
Study NCT06541548 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEXA
Description: The Lunar Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck.
Study NCT06029010 — intervention group
Intervention type: DRUG
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Follow clinical administration.
Study NCT05417867 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of stool and blood samples
Study NCT05417867 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT04539366 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT04539366 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT04539366 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT04539366 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT04539366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04539366 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT04539366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT04539366 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GD2-CAR-expressing Autologous T-lymphocytes
Description: Given IV
Study NCT04539366 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging Procedure
Description: Undergo standard imaging scans
Study NCT04539366 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging of the Heart
Description: Undergo cardiac MRI
Study NCT04539366 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT04539366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05803811 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Riboflavin
Description: Colon delivered vitamin B2 (Riboflavin) for 12 weeks
Study NCT01499693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Pantoprazole 20 mg
Description: oral dose, twice a day
Study NCT01499693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Pantoprazole 40 mg
Description: oral dose, once a day (morning)
Study NCT01499693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: oral dose, once a day (night)~Placebo will be administered at night in the group with 40mg magnesium pantoprazole to keep the blinding (so treatment administration is comparable w/the 20mg group).
Study NCT06431984 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: prick test
Description: self-sampling of capillary blood using the finger prick test method
Study NCT05803811 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Riboflavin
Description: Colon delivered vitamin B2 (Riboflavin) for 12 weeks
Study NCT05543928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTAP101
Description: CTAP101 Capsules is an extended-release (ER) oral formulation of calcifediol which was approved as Rayaldee® ER Capsules in June 2016 by the United States (US) Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI), defined as serum total 25-hydroxyvitamin D levels less than 30 ng/mL.
Study NCT05543928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06555744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZW191
Description: Administered intravenously
Study NCT05144633 — intervention group
Intervention type: DEVICE
Intervention: Auscultation
Description: This study will be to determine if the addition of Eko AI-assisted lung auscultation examination to a standard of care Pulmonary POCUS + assists with acute respiratory failure diagnosis.
Study NCT04561661 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous pinning
Description: Closed reduction, percutaneous pinning and plaster
Study NCT04561661 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Closed reduction, custom made orthosis and early mobilization
Study NCT04442061 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: Before the stimulation, identification of a motor hotspot and active motor threshold (AMT) will be performed. The TMS will be applied on the intermittent theta-burst modality (iTBS), i. e., 2 s of TBS trains (30 pulses) repeated every 10 s for 190 s, with a total number of 600 pulses (Huang et al, 2005). The whole TMS session, including preparation, will last up to 1h.~The sham TMS follows the same procedure of the active TMS without stimulating cortical tissue